Scilligence and TetraScience announce a new integration between their products to automate data management across R&D workflows. The integration will automatically collect data from instruments, software, and other sources via TetraScience’s Data Integration Platform and then enter that data into Scilligence’s suite of informatics solutions, most notably Scilligence ELN (Electronic Laboratory Notebook), RegMol (Compound Registration and Bioassay System) and Scilligence SDMS (Scientific Data Management System), three of its flagship products.

“The partnership with Scilligence aligns with our core beliefs that science should be a connected ecosystem driven to bring the best-of-breed applications together,” says Siping Wang, Co-Founder and CEO of TetraScience. “Through this new integration, we believe that we are further empowering every scientist to do more science while not limiting the instruments and software that they choose to use.”Moving R&D ForwardScilligence and TetraScience provide solutions that are designed to unlock the value of data collected in the lab environment. Paired together, Scilligence ELN, RegMol, and SDMS will be automatically populated with important data gathered by TetraScience, all with a few clicks of a button. By lessening the amount of time scientists spend working to input data, the integration will improve data integrity, increase efficiency, and begin to lay the foundation for any machine-learning and AI initiatives.“We are excited to join forces with TetraScience to provide better experiences and value to scientists in life sciences research,” says Jinbo Lee, Co-Founder and CSO of Scilligence Corporation. “This integration of technologies can not only provide significant time saving but also better data quality and regulatory compliance.”The PartnersAbout ScilligenceScilligence is an innovation leader of web-based cheminformatics and bioinformatics solutions for both small molecules and biologics. The Scilligence system is platform agnostic and modularized.  Its tools have been widely adopted by pharmaceutical, biotech, and chemical industries, universities, research institutes, and government agencies. Scilligence is the developer of the HELM (Hierarchical Editing Language for Macromolecules) Web Editor which works to standardize notation for biologics and facilitate the exchange of information between researchers. Visit: www.scilligence.com to learn more.About TetraScienceTetraScience is a Data Platform for Life Sciences R&D. Their technology helps life science companies advance discovery through insights into lab operations and comprehensive data integration. With TetraScience, laboratories connect critical information sources from instruments and lab systems to a cloud-based data platform. Data is centralized and standardized and available to downstream targets resulting in improved data management and streamlined process. In addition, TetraScience builds lab operation applications including Lab Monitoring via IoT technology and Lab Scheduling software. Visit www.tetrascience.com to learn more.DisclaimerThe statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.All product and service names mentioned are the trademarks of their respective companies.

Princeton University has licensed Scilligence Electronic Laboratory Notebook (ELN) and Inventory for Chemistry. The Scilligence platform has been deployed department-wide to support the university’s research efforts. “The Scilligence ELN system has greatly streamlined the users work by providing state-of-the-art tools and intuitive functionality. Also, the ability to be platform agnostic has greatly enhanced the experience in our heavily mixed environment. Finally, the support we have received is nothing short of exceptional. Very competent and friendly.” said Douglas Rosso, Senior IT Manager, Chemistry, Princeton University.

About Princeton University
Princeton University is a private Ivy League research university in Princeton, New Jersey. Founded in 1746 in Elizabeth as the College of New Jersey, Princeton is the fourth-oldest institution of higher education in the United States and one of the nine colonial colleges chartered before the American Revolution. Princeton University Chemistry was founded in 1795 and is one of the oldest departments of chemistry in the country.

The Global Health Drug Discovery Institute (GHDDI) Licenses Scilligence ELN

The Global Health Drug Discovery Institute (GHDDI) has licensed Scilligence Electronic Laboratory Notebook (ELN). Scilligence ELN will help GHDDI to strength collaboration within the organization by digitalizing experimental data. GHDDI researchers are now able to easily search and organize their experiments and associated files

.About The Global Health Drug Discovery Institute (GHDDI)

The Global Health Drug Discovery Institute (GHDDI) identifies and develops innovative approaches to new medicines for diseases most damaging to populations in the developing world. Being the first independent, not-for-profit research institute of its kind in China, GHDDI strives to establish a transformative drug discovery and translational platform with advanced biomedical research and development capabilities – from the bench to the bedside. GHDDI is jointly founded by the Bill and Melinda Gates Foundation, Tsinghua University, and the Beijing Municipal Government, and is closely partnered with the California Institute for Biomedical Research (Calibr) in scientific research.

About Scilligence

Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in the discovery and development of small molecule and biologic therapeutics.

The first-ever integration between an electronic lab notebook (ELN) and a chemistry research database will rely on FAIR principles to improve experiments and reduce manual curation

Scilligence, a provider of cheminformatics and bioinformatics solutions for the life sciences industry, has selected Elsevier’s Reaxys to help chemists improve efficiency and productivity.

Chemists often begin their work by following a manual process, searching for information and transferring that information between platforms, then typing in experimental details from references – all before going into the lab to run an experiment. This cumbersome process can introduce errors at multiple points. The ELN-Reaxys integration will allow chemists to search Reaxys for reactions of interest via the Scilligence electronic lab notebook (ELN) and retrieve appropriate reaction information and relevant references into their ELN. This will eliminate the need to copy/paste or draw manually, helping chemists streamline this process, maintain greater levels of transparency and reduce time and errors.

“ELNs are designed to capture data, but they are not the most efficient tools when it comes to searching for literature references and associating that with experiments,” said Jinbo Lee, Chief Scientific Officer and Co-founder, Scilligence. “Many ELN users don’t have the tendency to include reference information in their experiments, making it very difficult for other team members to figure out how a synthesis idea was originated. By integrating Scilligence ELN’s informatics capabilities with Reaxys’ data, we can increase efficiency, improve cross-referencing, and reduce manual errors.”

Further, making data FAIR (Findable, Accessible, Interoperable and Reusable) is an industry-wide expectation. Elsevier is at the forefront of the adoption of FAIR principles, with several Elsevier officials participating in the framework’s original committee.

“We are in an era of unprecedented opportunities to translate breakthrough science discoveries into therapies,” said Ivan Krstic, Director, Chemistry Solutions, Elsevier, the information analytics company specializing in science and health. “Still, IT and data issues present imposing barriers. Many organizations have data siloed in different departments, solutions and formats, and every time chemists want to add a new component, tool or data set to their review they can waste a lot of time normalizing that data to make it usable. That’s why it’s essential, and beneficial, for ELNs to integrate seamlessly with reliable data sources, to eliminate inefficient processes and empower chemists to answer their most pressing questions.”

The Scilligence-Reaxys alliance will, in the near future, lower even further the barriers between these silos. The Unified Data Model (UDM) data format maintained by the Pistoia Alliance will be established as the standard data exchange format for reactions between the Scilligence ELN and Reaxys. Hence, chemists will be able to transfer data from Reaxys into the Scilligence ELN. Also, data exported from the Scilligence ELN can be incorporated into Reaxys, reducing the need for the user to establish data transformation processes.

Reaxys retrieves literature, compound properties and chemical reaction data faster than any other solution and, together with Reaxys Medicinal Chemistry (RMC), offers pharma companies a ‘one stop shop’ chemistry ecosystem thanks to its integration capabilities, innovative APIs, and bioactivity data. The Reaxys platform contains over 240 years of unparalleled chemistry content, including: 119 million organic, inorganic and organometallic compounds, 46 million chemical reactions, 500 million published experimental facts, 16,000 chemistry related periodicals, Asian, European and US patents, and six indexing sources for a cross-disciplinary view of chemistry. RMC offers access to data from a vast repository of peer-reviewed journal articles and patents and is interoperable with Reaxys www.elsevier.com/solutions/reaxys.

—

About Scilligence
Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in the discovery and development of small molecule and biologic therapeutics.

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKeyand Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray’s Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com

Media contact

Christopher Capot, Global Communications
Elsevier
+1 917 704 5174
[email protected]

Originally posted by Elsevier: https://www.elsevier.com/about/press-releases/clinical-solutions/scilligence-and-elsevier-collaborate-to-enhance-lab-efficiency

Scilligence, a provider of mobile cheminformatics and bioinformatics for the life sciences industry, has joined the Accenture research platform open partner ecosystem, which will allow for the integration of Scilligence’s informatics solutions. Scilligence’s proprietary technologies address three main areas of R&D informatics needs: knowledge management and collaboration; project, workflow, and material management; and knowledge mining of unstructured data.

The research platform is an open partner ecosystem designed to help independent software vendors (ISVs) and life sciences companies collaborate more effectively to speed up drug discovery initiatives and enhance patient outcomes. Accenture’s project has been developed in collaboration with Merck and Amazon Web Services to enhance innovation and collaboration between life science companies and software providers. Scilligence is one of the first ISVs and organizations to integrate its technology and content into Accenture’s research platform.

“The Accenture research platform delivers an exciting cloud-based ecosystem for life sciences R&D informatics. Scilligence is proud to contribute to this platform,” said Jinbo Lee, CSO and co-founder of Scilligence.

Life science companies – such as pharmas, biotechs, contract research organizations, and research institutions – with a common informatics platform will have the ability to share their data more effectively and efficiently through the platform’s open application programming interface. This allows researchers to quickly access data and analyze data from multiple applications using a single interface in a secure and integrated environment. Scilligence provides cheminformatics and bioinformatics solutions to researchers easily and efficiently.

“The open partner ecosystem is one of the ways we’re bringing innovation to our clients through the Accenture research platform,” said Joe Donahue, a managing director in Accenture’s Life Sciences practice. “Through integration into the platform, users will gain access to Scilligence solutions that enhance knowledge sharing and productivity of researchers in discovery and development of small molecule and biologics therapeutics, which will ultimately lead to better patient outcomes.”

Click here to learn more about the Accenture Life Sciences research platform.

About Scilligence

Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in the discovery and development of small molecule and biologic therapeutics.

Contact
Krystyana Roman, Senior Marketing Specialist, Scilligence
[email protected]

Accenture has partnered with over 30 software vendors and other organizations to integrate their technology with Accenture’s research platform. Through this platform, vendors will have the opportunity to leverage the use of open, industry-standard application programming interfaces, enabling researchers to access innovative technologies. The ultimate goal of the project is to help life sciences organizations improve productivity, efficiency, and innovation in drug discovery R&D.

Scilligence is one of the vendors involved in this project and will join Accenture, Amazon, and Merck for a Research Platform Ecosystem integration workshop on November 28th from 8:00 – 10:30 AM during AWS re:Invent in Las Vegas. Accenture will demo Scilligence’s entity registration system and Scilligence will be a guest panelist during the event.

More information about the event and agenda can be found here: https://ti.to/rlsc/isv-workshop-las-vegas

The Pistoia Alliance, a global alliance of life science companies, vendors, publishers and academic groups, and Scilligence Corporation are pleased to announce the release of the major new extension to the HELM Web Editor. New functionalities enable the editor to support the representation of biomolecules with some structural uncertainty or ambiguity and also adds monomer and rule managers.

The therapeutic utilization of complex and unique biomolecules has become commonplace in drug discovery R&D. As a result, scientists have struggled to represent these entities in their informatics systems, forcing them to use various “pick and mix” approaches that include multiple nomenclatures and textual descriptions. HELM, the open biomolecular representation standard, has solved this problem by providing a means to represent various types of complex macromolecules (e.g. nucleotides, proteins, antibodies and antibody-drug conjugates) including the ones that contain unnatural amino acids or nucleotides/nucleosides.

The Pistoia Alliance formalized the HELM notation, originally developed by scientists at Pfizer, as an open standard in early 2013. The related toolkit and editor were later publicly released to the open source community. Since its release, HELM has been widely adopted by various organizations such as Bristol Myers Squibb, Pfizer, Novartis, Roche, GSK, Ionis, Merck and Co, Scilligence, NextMove Software, Dassault Systèmes BIOVIA, ChemAxon, Perkin-Elmer, quattro research, EMBL-EBI, NCBI (PubChem), and RDKit.

While the original HELM solved the problem of representing unnatural complex biomolecules, it held the basic assumption that a scientist would know everything about the structures being represented. In biology, however, this is not always the case, as various types of ambiguity or uncertainty may exist in some of these structures. A typical example is when the exact conjugation site of an antibody-drug conjugate cannot be determined. This left scientists with a difficult choice: either record the best guess of what the structure is or simply describe the structure textually instead of structurally, creating a gap in their corporate structural registries. This update to the web-editor enables scientists to incorporate into their structural representation a systematic description of a number of forms of ambiguity, thus allowing for the rigorous representation of structures, even when uncertainty is present.

“The HELM Web Editor already facilitates researchers’ ability to rigorously represent complex macromolecules in a technology-friendly manner. However, there was still a gap when it came to dealing with the very real-world scenario of structural uncertainty or ambiguity. Through this partnership with Scilligence, we have implemented the enhancements available in HELM 2.0 and further extended the capabilities and applicability of the open source tools,” said Sergio Rotstein, Director of Research Business Technology at Pfizer and Domain Lead for the Pistoia Alliance HELM initiative.

About Pistoia Alliance
The Pistoia Alliance is a global, not-for-profit members’ organization made up of life science companies, technology and service providers, publishers, and academic groups working to lower barriers to innovation in life science and healthcare R&D. It was conceived in 2007 and incorporated in 2009 by representatives of AstraZeneca, GSK, Novartis and Pfizer who met at a conference in Pistoia, Italy. Its projects transform R&D through pre-competitive collaboration. It overcomes common R&D obstacles by identifying the root causes, developing standards and best practices, sharing pre-competitive data and knowledge, and implementing technology pilots. There are currently over 80 member companies; members collaborate on projects that generate significant value for the worldwide life sciences R&D community, using the Pistoia Alliance’s proven framework for open innovation.
http://www.pistoiaalliance.org

About Scilligence
Scilligence is a leading innovator of web-based applications for life science research and development. Scilligence’s proprietary technologies provide a complete solution for all research informatics needs. Scilligence’s software tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.
https://scilligence.com

Contact
Krystyana Roman, Marketing Specialist, Scilligence
[email protected]
+1 (617) 520-4588

 Claire Bellamy, Project Manager, Pistoia Alliance
[email protected]
+44 7823 470513

CAMBRIDGE, Massachusetts – Scilligence, an innovative and sought-after integrated informatics software provider for life science R&D, has made it its mission is to deliver quality solutions globally. The company has already established offices in Europe and Asia and is expecting continued growth in these markets.

In addition to its team expansion, Scilligence now offers clients the option to host their informatics solutions on the cloud with a choice of data centers located in the United States (East and West Coast), Europe, Japan, China, and Singapore. The option to choose client’s own data center, not only offers Scilligence global customers the flexibility in terms of data hosting, but also ensures customers that data storage and management are in compliant with any local/regional regulatory as required.Scilligence offers independent deployment for each customer’s unshared data, which, guarantees IP protection and security. Scilligence has recently been awarded the ISO-27001:2013 certification, meeting the requirements of a world-class information security management system and once again ensuring client’s protection of its intellectual property and data.About ScilligenceScilligence is a leading innovator of web-based applications for life science research and development. Scilligence’s proprietary technologies provide a complete solution for R&D informatics needs. Scilligence’s software tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.https://scilligence.com

---

Scilligence has been awarded the ISO-9001:2015 and ISO-27001:2013 Certification for Design and Development of Web-based Cheminformatics and Bioinformatics Solutions.

The ISO 9001: 2015 certification has been awarded to Scilligence for meeting the criteria of a quality management system. The certification is based on principles such as a strong customer focus, dedication to constant improvement, implementing a top management system, and consistently meeting client requirements.

Scilligence received the ISO-27001:2013 for meeting the requirements of an information security management system and ensuring that client intellectual property and data remain secure and protected.

These levels of certification prove Scilligence’s constant commitment to quality and customer satisfaction.

About Scilligence
Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.

About Internation Organization for Standardization (ISO)
ISO is an independent, non-governmental and international organization, dedicated to developing standards to ensure efficiency, quality, and safety for products, services, and systems.
www.iso.org

The State Key Laboratory of Natural and Biomimetic Drugs at Peking University has licensed RegMol and Scilligence Inventory systems. This state-of-the-art informatics platform will centralize data and sample management, and facilitate collaborations at the State Key Laboratory.

About Scilligence
Scilligence is a leading innovator of web-based cheminformatics and bioinformatics solutions designed for any device, browser, and platform. Scilligence’s tools enhance the knowledge sharing and productivity of researchers in discovery and development of small molecule and biologic therapeutics.

The State Key Laboratory of Natural and Biomimetic Drugs at Peking University
The State Key Laboratory of Natural and Biomimetic Drugs, established in 1985, consists of an award-winning staff and multiple research groups making strides in a wide-range of disciplines including synthetic medicinal chemistry, natural drug, pharmacology, pharmaceutics, and more. The laboratory focuses on both fundamental and applied research in natural and biomimetic drugs to help tackle major diseases, such as tumors, cardio-cerebrovascular diseases, mental illnesses and viral infections. The laboratory accomplished the improbable in the fields of nucleic acid chemistry, carbohydrate chemistry, glycobiology, bioinorganic chemistry, natural product, and Chinese herbal medicine and has passed four assessments organized by the Ministry of Science and Technology with favorable results.